Vapotherm reveals business update following COVID-19 pandemic
Category: #health  By Nikita Chaurasia  Date: 2020-03-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vapotherm reveals business update following COVID-19 pandemic

Vapotherm, Inc., a global medical technology firm developing and manufacturing proprietary Hi-VNI Technology products, has reportedly announced an update on its business in response to the COVID-19 pandemic.

Sources cite that, as result of COVID-19, the company has witnessed increased demand for single-use disposables and Vapotherm Precision Flow® systems. The firm is working diligently to increase production capacity of its facility in New Hampshire, while confirming the safety of employees. To meet growing demand, Vapotherm has increased the number of production shifts and has recognized added opportunities to further enhance manufacturing capacity.

For the record, the HVNI (High Velocity Nasal Insufflation) technology, a refined form of Flow Oxygen therapy1, is a front-line theraphy for COVID-19 patients who are having difficulty in breathing. It is mask-free non-invasive ventilation for breathing patients and a first-line tool for easing respiratory distress—including dyspnea, hypoxemia, and hypercapnia. It also enables fast, safe treatment of undifferentiated respiratory distress with one convenient tool.

As per JAMA (Journal of American Medical Association research), around 19% of COVID-19 patients are struggling to breath and need support to get the oxygen they require to stay alive. The company’s hospital customers are leveraging this technology to aid COVID-19 patients in mild to modest respiratory distress, so that they can triage severe patients to a limited number of ventilators.

Joe Army, CEO and President at Vapotherm, said that customers and patients are of paramount importance for the company. Despite the challenging situation, the company’s entire team is supporting hospital customers as they treat coronavirus disease patients that are suffering with respiratory problems.

Army added that there is a significant surge in demand for respiratory products in Europe and the company has been preparing for similar surge in demand in the U.S. Vapotherm is working diligently to boost the production of disposables and precision flow systems for treating global pandemic.

Source Credit - https://www.businesswire.com/news/home/20200323005691/en/Vapotherm-Business-Update-Response-COVID-19-Pandemic

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Australian researchers discover anti-parasite drug that kills COVID-19
Australian researchers discover anti-parasite drug that kills COVID-19
By Nikita Chaurasia

Researchers at Monash University, Melbourne, have reportedly announced that they discovered that an anti-parasite medicine can kill the novel strain of the coronavirus (SARS-CoV-2) that has currently brought the world to a standstill. In a study pub...

Trump calls for a $2 trillion budget for U.S. infrastructure growth
Trump calls for a $2 trillion budget for U.S. infrastructure growth
By Nikita Chaurasia

U.S. President Donald Trump has reportedly called for a $2 trillion spending budget to repair the and build new and currently crumbling infrastructure including tunnels, bridges, and roads, seizing on the COVID-19 outbreak as well as interest rates t...

Analytics 4 Life reveals new data backing novel method to predict LVEDP
Analytics 4 Life reveals new data backing novel method to predict LVEDP
By Nikita Chaurasia

Analytics 4 Life, one the leading digital health company committed to improving existing diagnostic pathways, has reportedly presented data on its heart failure research at the ACC’s (American College of Cardiology) 69th Annual Scientific Sessi...